IGE Therapeutics Inc San Diego, CA - 92121

IGE Therapeutics Inc is categorized under Biotechnology Products and Services in San Diego, CA and active since 2003.

IGE Therapeutics Inc was established in 2003, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Biotechnology Products and Services business, which does work in the B2B market, and is classified as a Biotechnology Products and Services, under code number by the NAICS.

If you are seeking more information, feel free to contact Alex Chen at the company’s headquarters by writing to 6042 Cornerstone Ct., West, STE E, San Diego, California CA 92121 or by phoning (858) 368-0168. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: IGE Therapeutics Inc
Contact Person: Alex Chen
Address: 6042 Cornerstone Ct., West, STE E, San Diego, California 92121
Phone Number: (858) 368-0168
Website Address: igetherapeutics.com
Annual Revenue (USD): $1.000.000 to $2.499.999
Founded: 2003
Location Type: Headquarters
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Biotechnology Products and Services
Share This Business:

IGE Therapeutics Inc was started in 2003 to provide professional Biotechnology Products and Services under the SIC code and NAICS code . Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.

Feel free to contact Alex Chen for inquiries that concern IGE Therapeutics Inc by calling the company number (858) 368-0168, as your correspondence is most welcome. Additionally, the physical location of the headquarters of IGE Therapeutics Inc can be found at the coordinates 32.9014,-117.2079 as well as the street address 6042 Cornerstone Ct., West, STE E in San Diego, California 92121.

For its online presence, you may visit IGE Therapeutics Inc’s website at igetherapeutics.com and engage with its social media outlets through on Twitter and on Facebook.